GlassScriptPhysician profile
Craig M Linder
NPI 1215022058
$4,374.62
in general payments reported to CMS, 2019-2025
33 companies · $645 in 2025
The $645 reported for 2025 was more than what 80% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $312 · 2021: $685 · 2022: $1,046 · 2023: $670 · 2024: $605 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $792.66 | 2019-2023 | |
| Exeltis, USA INC. | $504.48 | 2019-2025 | Slynd |
| Aspira Women'S Health INC | $467.58 | 2022-2023 | Ova1 |
| Biogen, INC. | $340.32 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $205.95 | 2021-2025 | Thinprep 2000 Processor |
| Evofem Biosciences, INC. | $176.12 | 2021-2025 | Phexxi, Phexx, Solosec |
| Amgen INC. | $170.95 | 2019-2024 | Evenity |
| Allergan, INC. | $159.34 | 2019-2020 | |
| Myovant Sciences INC. | $157.72 | 2021-2022 | |
| Astellas Pharma US INC | $148.40 | 2023-2025 | Veozah, Myrbetriq |
| Avion Pharmaceuticals | $122.25 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $120.75 | 2021-2024 | |
| Shield Therapeutics INC | $120.22 | 2022-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $117.33 | 2024-2025 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $108.01 | 2020-2025 | Gardasil 9, Gardasil |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $105.43 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $61.99 | 2019-2021 | |
| Agile Therapeutics, INC. | $56.77 | 2021-2023 | Twirla |
| Millicent US INC | $51.86 | 2019-2025 | Femlyv |
| Mylan Pharmaceuticals INC. | $42.13 | 2020 | |
| Daiichi Sankyo INC. | $39.56 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.49 | 2020-2025 | |
| Amag Pharmaceuticals, INC. | $33.29 | 2019 | |
| Lupin INC. | $32.61 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.82 | 2022 | |
| Vertical Pharmaceuticals, LLC | $27.94 | 2019 | |
| Glaxosmithkline, LLC. | $24.98 | 2019 | |
| Pfizer INC. | $24.11 | 2025 | |
| Medtronic, INC. | $23.05 | 2022 | |
| Roche Diagnostics Corporation | $21.67 | 2021 | |
| Coopersurgical, INC. | $21.33 | 2022 | |
| Meditrina | $19.57 | 2023 | |
| Mission Pharmacal Company | $13.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Linder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.